Giusti R.M., Iwamoto K., Hatch E.E. Diethylstilbestrol revisited: a review of the long-term health effects. Ann. Intern. Med. 1995; 122(10): 778-88. Available at: https://www.ncbi.nlm.nih.gov/pubmed/?term=1.%09Giusti+R.M.%2C+Iwamoto+K.%2C+Hatch+E.E.+Diethylstilbestrol+revisited%3A+a+review+of+the+long-term+health+effects.+Annals+of+Internal+Medicine.+1995
Gore A.C., Crews D., Doan L.L., La Merrill M., Patisual H., Zota A., eds., Endocrine Society / IPEN. Introduction to Endocrine Disrupting Chemicals (EDCs). A Guide for Public Interest Organizations and Policy-makers. 2014. Available at: http://www.ipen.org/documents/introduction-endocrine-disrupting-chemicals-edcs
Global assessment of the state-of-the-science of endocrine disruptors. Geneva, Switzerland, World Health Organization, International Programme on Chemical Safety. 2002. Available at: http://www.who.int/ipcs/publications/new_issues/endocrine_ disruptors/en/
Trasande L., Zoeller T., Hass U., Kortenkamp A., Grandjean P., Peterson J. et al. Estimating Burden and Disease Costs of Exposure to Endocrine-Disrupting Chemicals in the European Union. J. Clinic Endocrinology & Metabolism. 2015; 100(4): 1245-55. Doi: https://doi.org/10.1210/jc.2014-4324
Vlachogianni T., van Vliet L. Endocrine - Disrupting Chemicals. A Lurking Threat. Athens: MIO-ECSDE; 2013. Available at: http://www.env-health.org/IMG/pdf/02102014 _joint_publication_edcs_mio_heal.pdf
Bergman A., Heindel J.J., Jobling S., Kidd K.A., Zoeller R.T., eds., WHO (World Health Organization)/UNEP (United Nations Environment Programme). The State of the Science of Endocrine Disrupting Chemicals. Geneva: UNEP/WHO; 2012. Available at: http://www.who.int/ceh/publications/endocrine/en/
The 32 to Leave Behind. The Most Well-founded List of EDCs Relevant for REACH. The International Chemical Secretariat (ChemSec). 2015. Available at: http://chemsec.org/publication/endocrine-disruptors,reach,sin-list/the-32-to-leave-behind-edcs-relevant-for-reach-2015/
Харчевникова Н.В. Система прогноза токсичности и опасности химических веществ, основанная на совместном использовании логических и численных методов. Гигиена и санитария. 2005; 6: 21-4.
Харчевникова Н.В., Блинова В.Г., Добрынин Д.А. Сопоставление различных моделей исследования связи «структура - астмагенная активность». НТИ. Сер. 2. Информ. процессы и системы. 2016; 2: 23-8.
Харчевникова Н.В., Блинова В.Г., Добрынин Д.А., Журков В.С. Использование интеллектуальной ДСМ-системы для анализа связи структуры нитрозамещенных бензолов с их мутагенной активностью в тесте Эймса. НТИ. Сер. 2. Информ. процессы и системы. 2015; 3: 6-11.
Vandenberg L.N., Colborn T., Hayes T.B., Heindel J.J., Jacobs D.R. Jr., Lee D.H. et al. Regulatory decisions on endocrine disrupting chemicals should be based on the principles of endocrinology. Reproductive Toxicology. 2013; 38: 1-15. Doi: 10.1016/j.reprotox.2013.02.002
Vandenberg L.N., Colborn T., Hayes T.B., Heindel J.J., Jacobs D.R., Jr., Lee D.H. et al. Hormones and endocrine-disrupting chemicals: Low-dose effects and nonmonotonic dose responses. Endocrine Reviews. 2012; 33(3): 378-455. Doi: 10.1210/er.2011-1050
Selye H. A Syndrome Produced by Diverse Nocuous Agents. Nature. 1936; 138(4): 32 (reprinted in J. Neuropsychiatry and Clinical Neurosciences. 1998; 10(2): 230a-231. Doi: http://dx.doi.org/10.1176/jnp.10.2.230a).
Саноцкий И.В. Вопросы возрастной токсикологии (Некоторые рекомендации по проведению экспериментальных исследований в области возрастной токсикологии). В кн.: Материалы Всесоюзного симпозиума по изучению влияния токсических веществ на молодой организм и вопросы возрастной токсикологии. М.; 1969: 32-7.
Жолдакова З.И., Синицына О.О. Закономерности развития токсического процесса в зависимости от стадий дезорганизации и адаптации. Гигиена и санитария. 2014; 5: 112-6.
Жолдакова З.И., Рахманин Ю.А., Синицына О.О. Комплексное действие веществ. Гигиеническая оценка и обоснование региональных нормативов. М.: АртЭстамп; 2007.
Endocrine Disrupting Chemicals Are Best Identified without the Use of Potency Cut-offs. The International Chemical Secretariat (ChemSec). 2016. Available at: http://chemsec.org/wp-content/uploads/2016/04/Identification-of-EDCs-and-potency-cut-offs-200416.pdf
Joint FAO/WHO expert meeting to review toxicological and health aspects of bisphenol A: final report, including report of stakeholder meeting on bisphenol A. 2010. Nov. 1-5; Ottawa; Canada. Geneva: WHO; 2011.
Survey of Bisphenol A in Russian foods. IPEN. 2010. Available at: http://www.ipen.org/ project-reports/survey-bisphenol-russian-foods
Rudel R.A., Perovich L.J. Endocrine disrupting chemicals in indoor and outdoor air. Atmos Environ. 2009; 43(1):170-81. Available at: https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC2677823/
Li A., Schoonover T.M., Zou Q., Norlock F., Conroy L.M., Scheff P.A., et al. Polycyclic aromatic hydrocarbons in residential air of ten Chicago area homes: Concentrations and influencing factors. Atmos Environ. 2005; 39(19): 3491-501.
Persson N.J., Pettersen H., Ishaq R., Axelman J., Bandh C., Broman D., et al. Polychlorinated biphenyls in polysulfide sealants-occurrence and emission from a landfill station. Environ Pollut. 2005; 138(1): 18-27. Doi: 10.1016/j.envpol.2005.02.021.
Аксёнова М.Г., Синицына О.О., Кириллов А.В., Козлова О.Б., Бурд С.Г. Использование препаратов вальпроевой кислоты в качестве референтного вещества для изучения молекулярно-генетического механизма «обезогенности» разрушителей эндокринной системы. Гигиена и санитария. 2017; 96(5): 422-7
Meirhaeghe A., Amouyel P. Impact of genetic variation of PPARγ in humans. Molecular Genetics and Metabolism. 2004; 83(1-2): 93-102.
Yates T., Davies M.J., Henson J., Edwardson C., Webb D., Bodicoat D.H. Effect of the PPARG2 Pro12Ala Polymorphism on Associations of Physical Activity and Sedentary Time with Markers of Insulin Sensitivity in Those with an Elevated Risk of Type 2 Diabetes. PLoS One. 2015; 10(5): e0124062. Doi: 10.1371/journal.pone.0124062.
Horiki M., Ikegami H., Fujisawa T., Kawabata Y., Ono M., Nishino M. et al. Association of Pro12Ala polymorphism of PPARγ gene with insulin resistance and related diseases. Diabetes Research and Clinical Practice. 2004; 66(12, Suppl.): S63-7.
Vaag A., Lund S.S. Non-obese patients with type 2 diabetes and prediabetic subjects: distinct phenotypes requiring special diabetes treatment and (or) prevention? Applied Physiology, Nutrition, and Metabolism. 2007; 32(5): 912-20.
Yu X., Wieczorek S., Franke A., Yin H., Pierer M., Sina C., et al. Association of UCP2 -866 G/A polymorphism with chronic inflammatory diseases. Genes and Immunity. 2009; 10(6):601-605. doi: 10.1038/gene.2009.29.
Beitelshees A.L., Finck B.N., Leone T.C., Cresci S., Wu J., Province M.A., et al. Interaction between the UCP2 -866G>A polymorphism, diabetes, and beta-blocker use among patients with acute coronary syndromes. Pharmacogenet Genomics. 2010; 20: 231-238. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2842450/
Andersen G., Dalgaard L.T., Justesen J.M., Anthonsen S., Nielsen T., Thørner L.W., et al. The frequent UCP2 -866G>A polymorphism protects against insulin resistance and is associated with obesity: a study of obesity and related metabolic traits among 17636 Danes. Int J Obes (Lond). 2013; 37(2):175-81. Doi: 10.1038/ijo.2012.22.
Oktavianthi S., Trimarsanto H., Febinia C.A., Suastika K., Saraswati M.R., Dwipayana P., et al. Uncoupling protein 2 gene polymorphisms are associated with obesity. Cardiovasc Diabetol. 2012; 11:41-51. Available at: https://www.ncbi.nlm.nih.gov/ pmc/articles/ PMC3412711/
de Souza B.M., Brondani L.A., Bouças A.P., Sortica D.A., Kramer C.K., Canani L.H., et al. Associations between UCP1 -3826A/G, UCP2 -866G/A, Ala55Val and Ins/Del, and UCP3 -55C/T polymorphisms and susceptibility to type 2 diabetes mellitus: case-control study and meta-analysis. PLoS One. 2013; 8(1):e54259. Doi: 10.1371/journal.pone.0054259.